Goldman Sachs’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-29,900
| Closed | -$2.54M | – | 5986 |
|
|
2022
Q3 | $2.54M | Sell |
29,900
-2,800
| -9% | -$249K | ﹤0.01% | 3766 |
|
|
2022
Q2 | $2.71M | Buy |
+32,700
| New | +$2.6M | ﹤0.01% | 3773 |
|
|
2022
Q1 | – | Sell |
-88,000
| Closed | -$7.78M | – | 6579 |
|
|
2021
Q4 | $7.78M | Hold |
88,000
| – | – | ﹤0.01% | 2992 |
|
|
2021
Q3 | $6.8M | Hold |
88,000
| – | – | ﹤0.01% | 3089 |
|
|
2021
Q2 | $7.34M | Hold |
88,000
| – | – | ﹤0.01% | 2997 |
|
|
2021
Q1 | $6.64M | Sell |
88,000
-37,500
| -30% | -$3.06M | ﹤0.01% | 2894 |
|
|
2020
Q4 | $11M | Buy |
125,500
+48,000
| +62% | +$3.81M | ﹤0.01% | 2381 |
|
|
2020
Q3 | $5.9M | Hold |
77,500
| – | – | ﹤0.01% | 2769 |
|
|
2020
Q2 | $9.56M | Sell |
77,500
-15,000
| -16% | -$1.49M | ﹤0.01% | 2305 |
|
|
2020
Q1 | $7.82M | Sell |
92,500
-16,600
| -15% | -$1.43M | ﹤0.01% | 2272 |
|
|
2019
Q4 | $9.22M | Buy |
109,100
+8,000
| +8% | +$604K | ﹤0.01% | 2491 |
|
|
2019
Q3 | $6.81M | Buy |
101,100
+98,600
| +3,944% | +$7.59M | ﹤0.01% | 2628 |
|
|
2019
Q2 | $214K | Buy |
+2,500
| New | +$214K | ﹤0.01% | 4762 |
|
|
2018
Q2 | – | Sell |
-80,000
| Closed | -$6.49M | – | 5662 |
|
|
2018
Q1 | $6.49M | Buy |
80,000
+30,000
| +60% | +$2.57M | ﹤0.01% | 2699 |
|
|
2017
Q4 | $4.46M | Buy |
50,000
+33,200
| +198% | +$2.89M | ﹤0.01% | 3105 |
|
|
2017
Q3 | $1.56M | Sell |
16,800
-3,200
| -16% | -$283K | ﹤0.01% | 4190 |
|
|
2017
Q2 | $1.82M | Hold |
20,000
| – | – | ﹤0.01% | 3917 |
|
|
2017
Q1 | $1.76M | Buy |
+20,000
| New | +$1.78M | ﹤0.01% | 3877 |
|
|
2016
Q2 | – | Sell |
-67,500
| Closed | -$5.57M | – | 7024 |
|
|
2016
Q1 | $5.57M | Sell |
67,500
-314,600
| -82% | -$25.6M | ﹤0.01% | 2643 |
|
|
2015
Q4 | $40M | Buy |
382,100
+147,100
| +63% | +$15.4M | 0.01% | 1288 |
|
|
2015
Q3 | $24.8M | Sell |
235,000
-55,900
| -19% | -$7.47M | 0.01% | 1568 |
|
|
2015
Q2 | $39.8M | Buy |
290,900
+6,900
| +2% | +$855K | 0.01% | 1281 |
|
|
2015
Q1 | $35.4M | Buy |
284,000
+115,000
| +68% | +$12.2M | 0.01% | 1349 |
|
|
2014
Q4 | $15.3M | Buy |
169,000
+79,000
| +88% | +$6.57M | ﹤0.01% | 2013 |
|
|
2014
Q3 | $6.49M | Sell |
90,000
-320,900
| -78% | -$21.1M | ﹤0.01% | 2762 |
|
|
2014
Q2 | $25.6M | Buy |
410,900
+192,700
| +88% | +$11.6M | 0.01% | 1604 |
|
|
2014
Q1 | $14.9M | Buy |
218,200
+197,500
| +954% | +$14.6M | ﹤0.01% | 2011 |
|
|
2013
Q4 | $1.46M | Sell |
20,700
-85,800
| -81% | -$5.83M | ﹤0.01% | 4396 |
|
|
2013
Q3 | $7.69M | Buy |
106,500
+15,300
| +17% | +$1.02M | ﹤0.01% | 2515 |
|
|
2013
Q2 | $5.08M | Buy |
+91,200
| New | +$5.68M | ﹤0.01% | 2721 |
|
Other funds holding BMRN
VCM
VPM
Goldman Sachs's BMRN Position: Q1 2026 in Review
Goldman Sachs reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q1 2026, selling an estimated $4.39M and leaving 379,596 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2371.
Goldman Sachs first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $262M in Q1 2018. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Goldman Sachs held 379,596 shares of BioMarin Pharmaceuticals worth $21.4M as of Q1 2026.
- Goldman Sachs sold 75,316 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.39M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2371 holding.
- Goldman Sachs first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's BioMarin Pharmaceuticals position peaked at $262M in Q1 2018.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.